Unintended Consequences Of REMS Weighed On Entyvio Review Team
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA chose to focus on communication instead of use restrictions to manage PML risk with Takeda’s Entyvio after looking long and hard at REMS options and the potential unintended effects of the risk management plans on drug utilization.